CAS 24730-10-7|Dihydroergocristine mesylate
Introduction：Basic information about CAS 24730-10-7|Dihydroergocristine mesylate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dihydroergocristine mesylate | ||
|---|---|---|---|
| CAS Number | 24730-10-7 | Molecular Weight | 707.83600 |
| Density | / | Boiling Point | 899.3ºC at 760 mmHg |
| Molecular Formula | C36H45N5O8S | Melting Point | / |
| MSDS | / | Flash Point | 497.7ºC |
Names
| Name | dihydroergocristine mesylate |
|---|---|
| Synonym | More Synonyms |
Dihydroergocristine mesylate BiologicalActivity
| Description | Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively[1]. |
|---|---|
| Related Catalog | Research Areas >>Neurological Disease |
| In Vitro | Dihydroergocristine (DHEC) (2-20 μM; 24 hours) has an IC50 value of 25 μM for inhibiting the activity of γ-secretase in T100 cells without affecting cell viability[1]. Dihydroergocristine (2-20 μM; 24 hours) inhibits cellular Aβ production and causes a dose-dependent accumulation of carboxy-terminal fragments of APP (APP-CTFs) in HEK293 and decreases γ-secretase activity in fibroblast cells[1]. Western Blot Analysis[1] Cell Line: WT HEK293 cells; Fibroblast cells Concentration: 2 μM, 5 μM, 10 μM, 20 μM Incubation Time: 24 hours Result: Increased APP-CTFs accumulation in a dose-dependent manner. |
| References | [1]. Lei X, et al. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides. Sci Rep. 2015 Nov 16;5:16541. |
Chemical & Physical Properties
| Boiling Point | 899.3ºC at 760 mmHg |
|---|---|
| Molecular Formula | C36H45N5O8S |
| Molecular Weight | 707.83600 |
| Flash Point | 497.7ºC |
| Exact Mass | 707.29900 |
| PSA | 180.96000 |
| LogP | 3.50660 |
| Vapour Pressure | 8.49E-35mmHg at 25°C |
| InChIKey | SPXACGZWWVIDGR-SPZWACKZSA-N |
| SMILES | CC(C)C1(NC(=O)C2CC3c4cccc5[nH]cc(c45)CC3N(C)C2)OC2(O)C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O.CS(=O)(=O)O |
| Storage condition | Store at RT |
| Water Solubility | H2O: 10 mg/mL |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 2643 mg/kg
- TOXIC EFFECTS :
- Behavioral - general anesthetic Behavioral - tremor Behavioral - convulsions or effect on seizure threshold
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,1381,1992
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 585 mg/kg
- TOXIC EFFECTS :
- Behavioral - general anesthetic Behavioral - tremor Behavioral - convulsions or effect on seizure threshold
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,1381,1992
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 91 mg/kg
- TOXIC EFFECTS :
- Behavioral - general anesthetic Behavioral - tremor Behavioral - convulsions or effect on seizure threshold
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,1381,1992
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >2500 mg/kg
- TOXIC EFFECTS :
- Behavioral - general anesthetic Behavioral - tremor Behavioral - convulsions or effect on seizure threshold
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,1381,1992
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 120 mg/kg
- TOXIC EFFECTS :
- Behavioral - general anesthetic Behavioral - tremor Behavioral - convulsions or effect on seizure threshold
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,1381,1992
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 70 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4176182
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- >1250 mg/kg
- TOXIC EFFECTS :
- Behavioral - tremor Behavioral - excitement Gastrointestinal - nausea or vomiting
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,1381,1992
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- >50 mg/kg
- TOXIC EFFECTS :
- Behavioral - tremor Behavioral - excitement Gastrointestinal - nausea or vomiting
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,1381,1992
Safety Information
| RIDADR | UN 1544 6 |
|---|---|
| WGK Germany | 2 |
| RTECS | KE7600000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
Articles3
More Articles| Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line. PLoS Negl. Trop. Dis. 9(1) , e0003493, (2015) Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, represents a very important public health problem in Latin America where it is endemic. Although mostly asymptomatic at its initial ... | |
| Roles of serotonergic and adrenergic receptors in the antinociception of selective cyclooxygenase-2 inhibitor in the rat spinal cord. Korean J. Pain 24(4) , 179-84, (2011) The analgesic mechanisms of cyclooxygenase (COX)-2 inhibitors have been explained mainly on the basis of the inhibition of prostaglandin biosynthesis. However, several lines of evidence suggest that t... | |
| The antiallodynic effect of intrathecal tianeptine is exerted by increased serotonin and norepinephrine in the spinal dorsal horn. Neurosci. Lett. 583 , 103-7, (2014) The purpose of this study was to validate the effects of tianeptine on serotonergic and noradrenergic neurotransmission in a rat model of neuropathic pain. Neuropathic pain was induced by ligating the... |
Synonyms
| dihydroergocristine methanesulphonate |
| DIHYDROERGOCRYSTINE METHANESULFONATE SALT |
| dihydroergocristine methane sulfonate |
| DIHYDROERGOCRISTINE METHANESULFONATE ERG OT ALKALOID,VASOC |
| Dihydroergocristine mesilate |
| 9,10-DihydroergocristineMethanesulfonate |
| EINECS 246-434-6 |
| dihydroergocristine methanesulfonate salt |
| Dihydroergocristine mesylate,(5'α,10α)-9,10-Dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(phenylmethyl)-ergotaman-3',6',18-trionemesylate |
| PACAP 1-38 |
| MFCD00153792 |
| dihydroergocristinmesilat |
| DIHYDROERGOCRISTINE MESYLATE |
| dihydroergocristine |
